We solve PROBLEMS and fill unmet NEEDS in medicine, through next-generation medical device technologies.At Aeon Technologies, we see VAST INEFFICIENCIES inherent in many medical technologies today, resulting in unmet needs, and immense OPPORTUNITIES open for those with breakthrough medical solutions…
We solve PROBLEMS and fill unmet NEEDS in medicine, through next-generation medical device technologies.
At Aeon Technologies, we see VAST INEFFICIENCIES inherent in many medical technologies today, resulting in unmet needs, and immense OPPORTUNITIES open for those with breakthrough medical solutions. We have pioneered and created a whole portfolio of them, and are prepared to take dominant positions in billion-dollar markets.
For example, worldwide per capita patient health care costs are spiraling out of control, more and more each year. The greatest culprit is not drug costs, but ever-growing daily use of the expensive traditional (X-ray, Ultrasound) and advanced imaging technologies (MRI, CT, PET, SPECT).
While they have substantially improved patient diagnosis, enabling physicians to view into the body, and its organs, all present imaging technologies are INVASIVE AND STIMULATORY, which means energy of some type enters (invasive) the body cavity, serves as a stimulant or otherwise excites activity to get a result (i.e. images created through the returning signals), and recognized harmful, or unknown long-term side effects are realized.
With trillions of dollars at stake, and continued, adamant usage in medicine, there is hidden CHAOS present. All of these DIAGNOSTIC IMAGING TECHS are quietly, if not secretly, FAILING US, costing us billions, while lining the pockets of the imaging technology providers and servicers, who will enjoy new significant new profits in the growing populations in Asia, China, and India, while the US works to introduce low cost health care to another 32 million more citizens.
Recent studies and facts are disturbing, and demonstrate Diagnostic Imaging tests are often:
• INCONCLUSIVE (20%-50% of advanced diagnostic imaging, for a variety of conditions, fail to provide information that improves patient diagnosis & treatment”). • UNNECESSARY (costing over $26 billion year), • REDUNDANT ($20 Billion a year wasted), • DUPLICITOUS (20% of radiology tests), • ERRONEOUS (fail to detect abnormalities in 25-32% of cases where disease was present, & misdiagnosing diseases in around 2 percent of cases that were actually normal; 25-30% radiologist internal error rates ); • ENDANGERING (Worldwide effective radiation exposure has doubled in past 10-15 yrs.)
We believe that in this age of “modern medicine,” where technology SHOULD result in greater precision, faster diagnosis, and reduction in both patient’s time, and health care costs; these facts and numbers are appalling! And an embarrassment to medicine! They demonstrate a GREAT NEED for significant change though breakthrough technology…. We have that technology, and have proven its accuracy and safety.
Where there is chaos, unmet needs, and billions in overlooked, bloated costs, there is always opportunity for the entrepreneur or company that can offer solutions through disruptive, new technologies that are BETTER, FASTER, AND CHEAPER.
Aeon’s mission is to exploit these opportunities, and establish ourselves as key niche players in the Medical device industry by developing and commercializing our own next-gen, non-invasive, energy-based, preventative diagnostic technologies, and other devices addressing large voids and needs that result in billion-dollar market opportunities, as per our Executive Summary in the Document Room.
Present diagnosis technologies DO NOT give an instant and accurate picture of overall organ health, is OPEN to physician error, and many organs simply CANNOT be medically assessed in this manner.
Our first product planned to market, answering these needs is our Multi-Organ Diagnostics System (MODS). It is comprised of a computer with software, specialized DC Volt Amp, and custom electrodes.
Its invention, arose from our pioneering work in electro-medicine with bio-potential measurements, and finding direct correlations to organ health diagnosis. Similar in some ways to the EKG, which is widely accepted and used in medicine today, we measure energy which is not introduced into, but given off by the body, and utilize software to measure bilateral asymmetry of the signals, to arrive at quick, reliable, easy to read, health assessment of 12 organs.
The KEY POINT TO UNDERSTAND with this technology, is that it is both non-invasive, and non-stimulatory, completely the opposite of all present imaging technologies in medicine today. Therefore it is inherently safe, and should favor FDA approval. As compared to prospective drug approvals, which are always full of risk, MODS expected approval period is much shorter and faster… 3 yrs. as compared to the 12 yr.+ average approval period for pharmaceuticals, and risk is certainly mitigated by our tech’s operation.
MODS is diagnostic screening tool, that instantly pinpoints the degree of different organ pathology/illness; advising the user of organ condition, and eventually naming the illness, prior to clinical symptomology. While it may be used as a standalone, easy to use organ diagnostics device, it may also be positioned as an important, companion device used BEFORE ordering any Patient Imaging: resulting in “more efficient,” relevant, and accurate utilization of traditional and advanced imaging in patient organ diagnosis.
With such use, our technology can help lower and control the above-recognized error rates, unnecessary costs, and other inherent issues of existing imaging technology use in organ diagnosis.
We have patents, have done over 1,200 exploratory clinicals at leading Los Angeles hospitals, and seek capital to get FDA approval and commercialize this safe, green, diagnostic device; completely changing the patient diagnostic exam, making it quicker, more accurate, and reducing the misdiagnosis, errors, redundancies, costs, and safety issues associated with present diagnostic imaging usage. This results in clear “objective-based’ physician imaging decisions, where they were previously completely subjectively based on the antiquated patient exam.
We believe we can 1) REDEFINE patient organ diagnosis, 2) be used as part of POTENTIALLY EVERY patient exam, & 3) take aim and CLAIM a piece of the $33 billion annual Global Diagnostic Imaging Market (Traditional X-Ray, Ultrasound; and Advanced Imaging: CT, PET, MRI, and Nuclear Medicine); and over $1.3 trillion-dollar annual US billing stream.
We feel confident that we can do this for a number of reasons, three of which are by being: BETTER, FASTER, AND CHEAPER than any indirect competing devices.
The market, further defined in our Executive Summary, should embrace the relatively low-cost $60,000 dollar MODS device, with its $150-$300 cost per use; no direct competitors; and unique advantages over existing and advanced technologies. Such existing, indirect competing imaging technologies can cost upwards of $1 million to over $3 million dollars, require dedicated shielded rooms costing over $500,000, cost up to $800,000 a year to run (MRI’s), and are typically replaced every 7 years, on average.
See “Proof of New Tech. NEED-Our MODS device vs. existing diagnostic imaging technologies,” in the document room for cited references on this info and comparisons.
Aeon is seeking $23.2 million capital to complete prototype development, FDA approval, testing, and commercialization of this Class III, pre-market approval, non-invasive, non-stimulatory device. We have a strong portfolio of other next-gen devices ensuring future growth opportunities; precipitating a consistent, powerful presence and brand in Medicine with multiple licensing, and other exits, including merger, acquisition, division sale(s), or IPO. This, as well as our 5 year projections, are included in the Executive Summary.
Most products in Aeon’s portfolio are “game-changers,” opening up billion-dollar, long-term market share opportunities, usually without ANY direct competition; and demonstrate clear benefits over indirect competitors.
P.S. We do not have any website, nor other public persona, for a number of reasons that will be made known upon further investor interest. Stealth is a key strategy.
Team (1)
Sectors Aeon Technologies serves:
Health Care
Consumer Goods
Life Sciences
Join Axial's Private M&A Platform
Aeon Technologies connects with qualified M&A advisors through the Axial Platform.
Looking for Buyers?
Reach this investor and hundreds more on Axial. No cost to advisors.
